Levi Marcellin, APRN
Adult Health · Orlando, FLNPI 1760097794
Payments from drug & device makers
Across 204 payments — averaging $19.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$457
- Regeneron Healthcare Solutions, Inc.$436
- Sanofi$423
- GSK$354
- Takeda Pharmaceuticals U.S.A., Inc.$354
- Boehringer Ingelheim$312
- plus $2K from 24 others
What the payments were for
- Food & beverage$3,91098%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 20 | $457 |
| Regeneron Healthcare Solutions, Inc. | 21 | $436 |
| Sanofi | 20 | $423 |
| GSK | 31 | $354 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $354 |
| Boehringer Ingelheim | 15 | $312 |
| Mallinckrodt Hospital Products Inc. | 8 | $204 |
| Actelion Pharmaceuticals US, Inc. | 9 | $191 |
| Merck | 8 | $159 |
| AbbVie | 5 | $113 |
| Grifols USA, LLC | 5 | $109 |
| Baxter Healthcare | 5 | $100 |
| Insmed, Inc. | 4 | $96 |
| Novartis | 5 | $92 |
| Bayer | 4 | $78 |
| Verona Pharma, Inc. | 4 | $74 |
| Harmony Biosciences LLC | 2 | $55 |
| Astellas Pharma US Inc | 2 | $54 |
| Amgen | 2 | $53 |
| Mylan Specialty L.p. | 3 | $53 |
| United Therapeutics Corporation | 2 | $46 |
| Pulmonx Corporation | 2 | $35 |
| Viatris Specialty LLC | 1 | $24 |
| Inogen, Inc. | 2 | $24 |
| Gilead | 1 | $23 |
| Covis Pharma GmbH | 1 | $23 |
| Philips North America LLC | 1 | $21 |
| Lilly USA, LLC | 1 | $18 |
| Pfizer | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$4,010 in reported general payments places this provider in the 85th percentile of 2,237 adult health providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 134 | $133,927 |
| Dupixent PenDupilumab | 17 | $66,607 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $28,441 |
| Spiriva RespimatTiotropium Bromide | 25 | $20,137 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $13,464 |
| SymbicortBudesonide/Formoterol Fumarate | 27 | $8,329 |
| DuleraMometasone/Formoterol | 12 | $4,352 |
| BreynaBudesonide/Formoterol Fumarate | 19 | $3,931 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 107 | $3,768 |
| Ventolin HfaAlbuterol Sulfate | 13 | $1,160 |
| Levocetirizine Dihydrochloride | 90 | $1,022 |
| Montelukast Sodium | 98 | $821 |
| Fluticasone Propionate | 40 | $536 |
| Prednisone | 98 | $248 |
| Doxycycline Hyclate | 29 | $211 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $354 | $147,391146 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $457 | $36,77052 claims |
| Boehringer IngelheimSpiriva Respimat | $312 | $20,13725 claims |
| MerckDulera | $159 | $4,35212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,237 adult health providers in Florida.
Other adult health in Orlando
- Sita SwamyOrlando$49K
- Alejandro Dela CruzOrlando$44K
- Andreina NeallOrlando$16K
- Jessica SettineriOrlando$14K
- Kristen KessingerOrlando$13K
- Angelo LewisOrlando$12K
- Patricia PagnottaMaitland$441K
- Carly KoelschSarasota$265K
- Norma SolisMiami$150K
- Ashley PontenbergWinter Park$136K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.